We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
Read MoreHide Full Article
Shares of Mirum Pharmaceuticals, Inc. (MIRM - Free Report) have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.
The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide.
In March 2024, the FDA approved Livmarli for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis (PFIC), a rare genetic disorder that causes liver failure.
Livmarli sales have been rising steadily since its approval and launch worldwide.
Factors Driving MIRM Stock
Image Source: Zacks Investment Research
The majority of Mirum’s revenues are now being driven by Livmarli. In the first nine months of 2024, Livmarli generated sales worth $149.2 million, up 48.7% on a year-over-year basis. The continued demand for Livmarli is driving the top line and the momentum is expected to continue in the future quarters.
Management expects Livmarli product revenues to increase in future quarters owing to the strong global adoption of the product.
Mirum recently initiated the phase III EXPAND study, which is a label expansion opportunity for Livmarli in additional settings of cholestatic pruritus.
The European Commission approved Livmarli oral solution for the treatment of PFIC in patients aged three months and above in July 2024. The drug is also approved for treating cholestatic pruritus in PFIC patients aged 12 months and above in the United States.
Per management, the approval of Livmarli for the PFIC indication should help Mirum tap a space with significant potential.
MIRM's Other Pipeline Updates
In August 2023, Mirum acquired all assets of Travere Therapeutics’ bile acid products, which added two other products to its commercial portfolio — Cholbam (cholic acid) capsules and Chenodal (chenodiol) tablets. Cholbam is approved for treating bile acid synthesis disorders and Zellweger spectrum disorders.
In June 2024, a new drug application for chenodiol for treating cerebrotendinous xanthomatosis (CTX) patients was filed in the United States. The FDA has set a target action date of Dec. 28, 2024.
Chenodiol is not currently approved but has received a medical necessity medicine status from the FDA for the treatment of CTX, a rare autosomal genetic disorder.
Mirum’s pipeline candidate, volixibat, is currently being evaluated in two phase IIb studies for treating patients with primary biliary cholangitis (the VANTAGE study) and primary sclerosing cholangitis (the VISTAS study).
Strong uptake of Livmarli, potential diversification of its commercial portfolio as well as the successful development of volixibat should push the stock upward in 2025.
In the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time. Year to date, shares of IMCR have declined 52%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 25.57%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Loss per share estimates for 2025 have narrowed from $1.54 to 54 cents during the same time. Year to date, shares of SPRO have declined 23.1%.
SPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time. Year to date, shares of CSTL have surged 41%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
Shares of Mirum Pharmaceuticals, Inc. (MIRM - Free Report) have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.
The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide.
In March 2024, the FDA approved Livmarli for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis (PFIC), a rare genetic disorder that causes liver failure.
Livmarli sales have been rising steadily since its approval and launch worldwide.
Factors Driving MIRM Stock
Image Source: Zacks Investment Research
The majority of Mirum’s revenues are now being driven by Livmarli. In the first nine months of 2024, Livmarli generated sales worth $149.2 million, up 48.7% on a year-over-year basis. The continued demand for Livmarli is driving the top line and the momentum is expected to continue in the future quarters.
Management expects Livmarli product revenues to increase in future quarters owing to the strong global adoption of the product.
Mirum recently initiated the phase III EXPAND study, which is a label expansion opportunity for Livmarli in additional settings of cholestatic pruritus.
The European Commission approved Livmarli oral solution for the treatment of PFIC in patients aged three months and above in July 2024. The drug is also approved for treating cholestatic pruritus in PFIC patients aged 12 months and above in the United States.
Per management, the approval of Livmarli for the PFIC indication should help Mirum tap a space with significant potential.
MIRM's Other Pipeline Updates
In August 2023, Mirum acquired all assets of Travere Therapeutics’ bile acid products, which added two other products to its commercial portfolio — Cholbam (cholic acid) capsules and Chenodal (chenodiol) tablets. Cholbam is approved for treating bile acid synthesis disorders and Zellweger spectrum disorders.
In June 2024, a new drug application for chenodiol for treating cerebrotendinous xanthomatosis (CTX) patients was filed in the United States. The FDA has set a target action date of Dec. 28, 2024.
Chenodiol is not currently approved but has received a medical necessity medicine status from the FDA for the treatment of CTX, a rare autosomal genetic disorder.
Mirum’s pipeline candidate, volixibat, is currently being evaluated in two phase IIb studies for treating patients with primary biliary cholangitis (the VANTAGE study) and primary sclerosing cholangitis (the VISTAS study).
Strong uptake of Livmarli, potential diversification of its commercial portfolio as well as the successful development of volixibat should push the stock upward in 2025.
Mirum Pharmaceuticals, Inc. Price
Mirum Pharmaceuticals, Inc. price | Mirum Pharmaceuticals, Inc. Quote
MIRM's Zacks Rank & Key Picks
Mirum currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the biotech sector are Immunocore Holdings plc (IMCR - Free Report) , Spero Therapeutics, Inc. (SPRO - Free Report) and Castle Biosciences, Inc. (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time. Year to date, shares of IMCR have declined 52%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 25.57%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Loss per share estimates for 2025 have narrowed from $1.54 to 54 cents during the same time. Year to date, shares of SPRO have declined 23.1%.
SPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time. Year to date, shares of CSTL have surged 41%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.